MarketPeel
Insider Trading Intelligence
Pricing
…
JF

Jonathan P. Foster

MBRX
CHIEF FINANCIAL OFFICER · MOLECULIN BIOTECH, INC. · CIK 0001545414
FILING MIX · LIFETIME49%/51%
BUYS
26
SELLS
27
TOTAL VALUE
$141.8K
COMPANIES
2
ACTIVE SINCE
Jul 2020
HOLDINGS NOW
12,340
AVG SELL PX
$0.88
TRADE KIND
SHOWING 53 / 53
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons · 2 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Jonathan P. Foster, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+66.67%+21.02%+1.76%+19.27%+7.27%—
14d3+66.67%+31.69%+2.16%+29.53%+38.55%—
30d3+33.33%+97.59%+4.65%+92.94%+153.08%—
60d3+33.33%+65.97%+7.27%+58.70%+99.77%—
90d3+33.33%+17.28%+10.61%+6.66%+37.79%—
180d3+33.33%-49.66%+13.88%-63.54%-56.47%—
1y3+33.33%-65.73%+25.37%-91.10%-81.99%—
2y3(2 pending)+0.00%-98.39%+47.45%-145.84%-145.84%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
MBRX · 12,340 shares · as of Jun 22, 2026
0504,4241,008,8481,513,2712,017,695202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 26 buys / 27 sellsCOVERAGE · 24 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
41$3.12$12812,340Jun 22, 2026Jun 24, 2026 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
174——147,718Jun 22, 2026Jun 24, 2026 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASE
Chief Financial Officer
174——12,381Jun 22, 2026Jun 24, 2026 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASE
Chief Financial Officer
109——12,238Jun 20, 2026Jun 24, 2026 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
109——147,892Jun 20, 2026Jun 24, 2026 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
31$2.88$8912,207Jun 20, 2026Jun 24, 2026 ↗View →
EMPD
EMPERY DIGITAL INC.
SALE
2——0Feb 18, 2026Feb 20, 2026 ↗View →
EMPD
EMPERY DIGITAL INC.
SALE
1——0Feb 18, 2026Feb 20, 2026 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASEGRANT
Stock grant
600,000——1,617,695Nov 12, 2025Nov 14, 2025 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASEGRANT
Stock grant
400,000——2,017,695Nov 12, 2025Nov 14, 2025 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASE
Chief Financial Officer
20,625——308,212Nov 4, 2025Nov 6, 2025 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
5,023$0.50$2.5K303,189Nov 4, 2025Nov 6, 2025 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
20,625——1,017,695Nov 4, 2025Nov 6, 2025 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASE
Chief Financial Officer
270,270$0.37$100.0K287,587Jun 23, 2025Jun 23, 2025 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
810,810——1,038,320Jun 23, 2025Jun 23, 2025 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASE
Chief Financial Officer
4,328——18,371Jun 22, 2025Jun 23, 2025 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
1,054$0.27$28117,317Jun 22, 2025Jun 23, 2025 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
4,328——227,510Jun 22, 2025Jun 23, 2025 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
661$0.27$17614,043Jun 20, 2025Jun 23, 2025 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
2,711——231,838Jun 20, 2025Jun 23, 2025 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASE
Chief Financial Officer
2,711——14,704Jun 20, 2025Jun 23, 2025 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASE
Chief Financial Officer
833——12,196Jun 16, 2025Jun 18, 2025 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
203$0.69$13911,993Jun 16, 2025Jun 18, 2025 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
833——230,684Jun 16, 2025Jun 18, 2025 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASEGRANT
Stock grant
65,000——129,837Nov 4, 2024Nov 6, 2024 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASEGRANT
Stock grant
82,500——212,337Nov 4, 2024Nov 6, 2024 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASEGRANT
Stock grant
19,180——231,517Oct 25, 2024Nov 6, 2024 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASE
Chief Financial Officer
4,329——12,416Jun 22, 2024Jun 25, 2024 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
4,329——64,837Jun 22, 2024Jun 25, 2024 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
1,053$3.74$3.9K11,363Jun 22, 2024Jun 25, 2024 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
636$3.78$2.4K8,087Jun 20, 2024Jun 21, 2024 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASE
Chief Financial Officer
2,712——8,723Jun 20, 2024Jun 21, 2024 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
2,712——69,166Jun 20, 2024Jun 21, 2024 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
834——71,878Jun 16, 2024Jun 18, 2024 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
196$4.14$8116,011Jun 16, 2024Jun 18, 2024 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASE
Chief Financial Officer
834——6,207Jun 16, 2024Jun 18, 2024 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASE
Chief Financial Officer
28,986$0.69$20.0K80,556Dec 26, 2023Dec 27, 2023 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASEGRANT
Stock grant
150,000——830,938Jun 22, 2023Jun 26, 2023 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASEGRANT
Stock grant
259,688——1,090,626Jun 22, 2023Jun 26, 2023 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASE
Chief Financial Officer
40,667——61,246Jun 20, 2023Jun 22, 2023 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
9,676$0.57$5.5K51,570Jun 20, 2023Jun 22, 2023 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
40,667——680,938Jun 20, 2023Jun 22, 2023 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
3,044$0.57$1.7K20,579Jun 16, 2023Jun 20, 2023 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
12,500——721,605Jun 16, 2023Jun 20, 2023 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASE
Chief Financial Officer
12,500——23,623Jun 16, 2023Jun 20, 2023 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASEGRANT
Stock grant
162,667——734,105Jun 20, 2022Jun 22, 2022 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASEGRANT
Stock grant
155,000——571,438Jun 20, 2022Jun 22, 2022 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASE
Chief Financial Officer
12,500——14,167Jun 16, 2022Jun 21, 2022 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
3,044$1.33$4.0K11,123Jun 16, 2022Jun 21, 2022 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
SALE
Chief Financial Officer
12,500——416,438Jun 16, 2022Jun 21, 2022 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASEGRANT
Stock grant
50,000——428,938Jun 16, 2021Jun 21, 2021 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASEGRANT
Stock grant
108,770——378,938Jun 16, 2021Jun 21, 2021 ↗View →
MBRX
MOLECULIN BIOTECH, INC.
PURCHASEGRANT
Stock grant
460,000——1,621,000Jul 2, 2020Jul 7, 2020 ↗View →
Other insiders · MBRX
Loading peer insiders…
About this filer
CIK 0001545414
ROLE
Chief Financial Officer
PRIMARY
MBRX
COMPANIES
2
ACTIVE SINCE
Jul 2020
MARKETPEEL · /INSIDER/0001545414DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback